Bora Pharmaceuticals Co., LTD.

TWSE:6472 Stock Report

Market Cap: NT$76.2b

Bora Pharmaceuticals Future Growth

Future criteria checks 4/6

Bora Pharmaceuticals is forecast to grow earnings and revenue by 16.2% and 22.5% per annum respectively. EPS is expected to grow by 15.7% per annum. Return on equity is forecast to be 27.3% in 3 years.

Key information

16.2%

Earnings growth rate

15.7%

EPS growth rate

Pharmaceuticals earnings growth48.1%
Revenue growth rate22.5%
Future return on equity27.3%
Analyst coverage

Good

Last updated03 Dec 2024

Recent future growth updates

Recent updates

Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem

Nov 21
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem

Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?

Oct 04
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects

Jul 18
Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects

Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

Jun 13
Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Apr 10
Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Apr 08
Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Mar 14
Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Apr 30
Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Mar 17
Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

Feb 17
Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

Jan 27
New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

Jan 19
Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Dec 29
We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Dec 09
Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Earnings and Revenue Growth Forecasts

TWSE:6472 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202627,6075,168N/A7,2792
12/31/202524,1095,2814,2885,3996
12/31/202419,5674,3471,6363,3594
9/30/202416,7053,9001,8142,366N/A
6/30/202414,1663,187-5751,011N/A
3/31/202412,2772,7072,3063,871N/A
12/31/202314,2003,0303,1834,614N/A
9/30/202316,2932,8682,8484,257N/A
6/30/202315,9422,7044,0384,362N/A
3/31/202314,1582,2523,6843,926N/A
12/31/202210,4941,3921,8102,010N/A
9/30/20226,3461,1281,3221,465N/A
6/30/20224,8116978441,029N/A
3/31/20224,6505941,0791,389N/A
12/31/20214,9007508731,237N/A
9/30/20214,4181,045636975N/A
6/30/20213,626963286603N/A
3/31/20212,794868-261-43N/A
12/31/20201,80057826178N/A
9/30/20201,523191-608188N/A
6/30/20201,513232-317415N/A
3/31/20201,521262-211478N/A
12/31/20191,529305-467232N/A
9/30/20191,517355373449N/A
6/30/20191,492283305373N/A
3/31/20191,515267262318N/A
12/31/20181,372443130167N/A
9/30/20181,107351-56-40N/A
6/30/2018846330N/A-218N/A
3/31/2018525274N/A-263N/A
12/31/201735814N/A20N/A
9/30/201732317N/A2N/A
6/30/201729722N/A22N/A
3/31/201729124N/A5N/A
12/31/201628325N/A-18N/A
9/30/201627323N/A-20N/A
6/30/201626018N/A-22N/A
3/31/201624726N/A-4N/A
12/31/201523834N/A9N/A
9/30/201523630N/A18N/A
6/30/201523428N/A13N/A
3/31/201522623N/A16N/A
12/31/201421817N/A18N/A
9/30/201418216N/A8N/A
6/30/201415416N/A0N/A
3/31/201412310N/A-11N/A
12/31/2013934N/A-21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6472's forecast earnings growth (16.2% per year) is above the savings rate (1.1%).

Earnings vs Market: 6472's earnings (16.2% per year) are forecast to grow slower than the TW market (19.2% per year).

High Growth Earnings: 6472's earnings are forecast to grow, but not significantly.

Revenue vs Market: 6472's revenue (22.5% per year) is forecast to grow faster than the TW market (12.1% per year).

High Growth Revenue: 6472's revenue (22.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 6472's Return on Equity is forecast to be high in 3 years time (27.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 09:20
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bora Pharmaceuticals Co., LTD. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCapital Securities Corporation
Jianzheng WuCapital Securities Corporation
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.